BPIFB4 and infection: In vitro experiments on PBMCs have showed a biphasic immune response mediated by recombinant LAV-BPIFB4 (rLAV-BPIFB4) that in the first phase of the infection induced a hyperactivation of CD4+ and CD8+ lymphocytes that decreases in the ending phase of the treatment demonstrating that this longevity-associated variant has a considerable immune shaping activity.